Quratis

Quratis Inventory

The Inventory of Quratis (348080.KQ) as of Nov 22, 2026 is 866.20 M KRW. In the previous year, Inventory was 1.62 B KRW — a change of -46.59% (lower).

Inventory

866.20 MKRW

YoY

-46.59%

Last updated:

Inventory of Quratis is 2025 866.20 M KRW. Inventory of Quratis was 2024 1.62 B KRW. It decreases by -46.59% lower compared to the previous year.

The Quratis Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2020
0.00 KRW
Jan 1, 2021
1.65 B KRW
Jan 1, 2022
3.03 B KRW
Jan 1, 2023
1.56 B KRW
Jan 1, 2024
1.62 B KRW
Jan 1, 2025
866.20 M KRW
The Quratis Inventory history
YEARInventoryYoY
866.20 MKRW-46.59%
1.62 BKRW+4.04%
1.56 BKRW-48.60%
3.03 BKRW+83.35%
1.65 BKRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quratis Stock analysis

What does Quratis do? Quratis, Inc. generates revenue through the manufacture and sale of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines, as well as peptide nucleic acid complex products. The company provides Cell Penetrating Peptide (CPP) platform services to clients in the pharmaceutical sector. Revenue streams are derived from the development and research activities related to vaccine products, with a focus on tuberculosis and COVID-19 vaccine research for adult and adolescent populations. Quratis targets pharmaceutical companies and research institutions seeking advanced vaccine development solutions. The company's CPP platform services are utilized by clients requiring innovative delivery systems for therapeutic applications. Revenue is generated through direct sales of vaccine products and service contracts for CPP platform usage, primarily serving the pharmaceutical industry segment focused on vaccine development and research. The firm's primary products include tuberculosis vaccines for adults and adolescents, COVID-19 vaccines, and peptide nucleic acid complex. These products are sold to pharmaceutical companies and research organizations. The company's revenue model combines product sales with service-based offerings, where the Cell Penetrating Peptide (CPP) platform services represent a key revenue stream alongside vaccine sales. Quratis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quratis stock

Inventory of Quratis is 866.20 M KRW in 2025.

Inventory of Quratis changed from 1.62 B KRW to 866.20 M KRW, representing a -46.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Quratis since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Quratis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Quratis

All Key Metrics — Quratis